Arcturus Therapeutics (ARCT) Tops Q3 EPS by 48c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($1.33), $0.48 better than the analyst estimate of ($1.81). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $3.42 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• GameStop (GME) Tops Q2 EPS by 8c
• United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance